Can hyperbaric oxygen therapy (HBOT) increase telomere length?

HBOT and Telomere Length: Evidence Summary

Hyperbaric oxygen therapy (HBOT) can significantly increase telomere length in peripheral blood cells by over 20-37% and reduce cellular senescence markers by up to 37%, based on prospective human trials. 1

Key Evidence from Human Studies

The strongest and most recent direct evidence comes from a 2020 prospective trial that enrolled 35 healthy adults aged ≥64 years who received 60 daily HBOT sessions 1. This study demonstrated:

• T helper, T cytotoxic, natural killer, and B cells all showed telomere lengthening exceeding 20%
• B cells exhibited the most dramatic response: 25.68% increase at session 30,29.39% at session 60, and 37.63% post-HBOT (all p<0.01)
• Senescent T helper cells decreased by 37.30% (p<0.0001)
• Senescent T-cytotoxic cells decreased by 10.96% (p=0.0004)

A 2022 single-subject case report corroborated these findings, showing telomere length doubled after 60 HBO2 sessions, alongside improvements in cognitive function (3.1-3.8%), cerebral perfusion (43-52%), and physical performance 2.

Mechanistic Context

The telomere lengthening effect appears paradoxical given that oxygen exposure typically accelerates aging 3. However, intermittent hyperoxic exposures using specific HBOT protocols can trigger regenerative responses similar to those normally occurring during hypoxia 1, 4.

Earlier research in divers exposed to intense hyperbaric oxygen showed initial telomere elongation in granulocytes and naïve T cells (but not memory T cells or B cells), attributed to:

• Telomerase activation in naïve T cells
• Repopulation from undifferentiated hematopoietic cells with longer telomeres in granulocytes 5

Critical caveat: This same diver study documented subsequent telomere length reduction after the initial elongation, suggesting enhanced cell turnover that may accelerate tissue aging over time 5.

Clinical Protocol Specifications

The effective protocol from the landmark 2020 study 1:

• 60 daily sessions over approximately 3 months
• Standard HBOT parameters (typically 2.0-2.8 ATA, 60-90 minutes)
• Effects measured at baseline, session 30, session 60, and 1-2 weeks post-treatment

Important Limitations & Caveats

1. Sample size remains small: The primary evidence comes from 35 subjects in one trial and one case report
2. Long-term durability unknown: Follow-up data beyond weeks post-treatment are lacking
3. Potential biphasic response: The diver study suggests initial lengthening may be followed by accelerated shortening with continued exposure 5
4. Population-specific: Studies focused on healthy older adults (≥64 years); effects in younger populations or disease states are unclear
5. No established clinical indication: Current HBOT guidelines focus exclusively on acute conditions (carbon monoxide poisoning, decompression sickness, wound healing) 6. No guideline recommends HBOT for telomere lengthening or anti-aging purposes

Practical Considerations

HBOT for telomere lengthening remains investigational and is not part of standard medical practice. The therapy requires:

• Access to specialized hyperbaric facilities
• 60 consecutive daily sessions (significant time/cost commitment)
• Acceptance of known HBOT risks: barotrauma, transient myopia, claustrophobia, rare seizures 7
• Recognition that oxygen toxicity can occur with prolonged high-concentration exposure 6

The evidence suggests biological plausibility and preliminary efficacy, but this application lacks regulatory approval, long-term safety data, and validation in larger randomized controlled trials. Any use for telomere lengthening should be considered experimental and discussed transparently with patients regarding the limited evidence base.